An overview of the utilization and cost for selected oral antineoplastic agents, with discussion regarding oncology in general, as well as the topic of adherence.
Vinod Swarna, MS, MCA
Advertisement
Articles by Vinod Swarna, MS, MCA
New and forthcoming oral anticoagulants, which do not require prothrombin time monitoring, will offer patients and providers additional therapeutic options.
Incivek and Victrelis, approved for Hepatitis C within weeks of each other in May 2011, look to change the way the disease is treated.
Advertisement
Latest Updated Articles
- Initial Prescription Utilization of the New Hepatitis C Agents
Published: April 5th 2012 | Updated:
- Prescription Utilization of the Oral Anticoagulants
Published: May 31st 2012 | Updated:
- Oral Oncology: Utilization of Selected Oral Antineoplastic Enzyme Inhibitor Agents
Published: August 2nd 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
2
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
3
Study Shows Growing Confidence in Cell and Gene Therapies Across the Care Continuum
4
FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension
5
